C
18.74
-0.14 (-0.74%)
| Previous Close | 18.88 |
| Open | 18.80 |
| Volume | 204,845 |
| Avg. Volume (3M) | 1,273,838 |
| Market Cap | 4,581,350,912 |
| Price / Earnings (TTM) | 49.32 |
| Price / Sales | 9.70 |
| Price / Book | 9.85 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Profit Margin | -46.34% |
| Operating Margin (TTM) | 11.41% |
| Diluted EPS (TTM) | -0.920 |
| Quarterly Revenue Growth (YOY) | 20.10% |
| Total Debt/Equity (MRQ) | 2.92% |
| Current Ratio (MRQ) | 1.82 |
| Operating Cash Flow (TTM) | 143.01 M |
| Levered Free Cash Flow (TTM) | 112.16 M |
| Return on Assets (TTM) | 6.05% |
| Return on Equity (TTM) | -115.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Software - Infrastructure (US) | Mixed | Mixed |
| Software - Infrastructure (Global) | Mixed | Mixed | |
| Stock | Cellebrite DI Ltd. | Bullish | Mixed |
AIStockmoo Score
0.8
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.75 |
|
Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker. |
|
| Sector | Technology |
| Industry | Software - Infrastructure |
| Investment Style | Mid Growth |
| % Held by Insiders | 45.54% |
| % Held by Institutions | 47.76% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (B of A Securities, 33.40%) | Buy |
| Median | 24.00 (28.07%) | |
| Low | 23.00 (Lake Street, 22.73%) | Buy |
| Average | 24.00 (28.07%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 19.28 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 13 Nov 2025 | 25.00 (33.40%) | Buy | 19.28 |
| JP Morgan | 13 Nov 2025 | 24.00 (28.07%) | Buy | 19.28 |
| Lake Street | 13 Nov 2025 | 23.00 (22.73%) | Buy | 19.28 |
| Needham | 13 Nov 2025 | 24.00 (28.07%) | Buy | 19.28 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Dec 2025 | Announcement | Cellebrite Completes Acquisition of Corellium, Extending the Industry’s Most Advanced AI-Powered Digital Investigation Platform |
| 12 Nov 2025 | Announcement | Cellebrite Announces Third-Quarter 2025 Results |
| 30 Oct 2025 | Announcement | Cellebrite Appoints Holly Windham as General Counsel and Chief Compliance Officer |
| 30 Oct 2025 | Announcement | Cellebrite Appoints Holly Windham as General Counsel and Chief Compliance Officer |
| 28 Oct 2025 | Announcement | Actor, Host, Artist and Anti-Human Trafficking Advocate Terry Crews to Headline Cellebrite C2C User Summit 2026 |
| 17 Oct 2025 | Announcement | Cellebrite to Report Third-Quarter 2025 Financial Results on November 12, 2025 |
| 15 Oct 2025 | Announcement | Cellebrite Expands Market Reach with Innovations in Agentic AI, Cloud and Device Virtualization for the Company’s Autumn 2025 Release |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |